Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
2020
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at = 4 mg/L. It had potent activity against ESBL positive Enterobacteriaceae, carbapenem resistant Enterobacteriaceae, and non-fermenting Gram-negative bacilli including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter spp. Amikacin, ceftazidime/avibactam and meropenem had appreciable activity against non-CRE Enterobacteriaceae No comparators were active against MDR P. aeruginosa. Only trimethoprim/sulfamethoxazole had appreciable activity against S. maltophilia Overall, cefiderocol was associated with the lowest level of resistance.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
16
Citations
NaN
KQI